A Study in Patients With Advanced Cancers
Recruiting now · Phase 1/Phase 2
Conditions studied: Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
In brief
A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.
Key facts
- Study ID
- NCT05320588
- Run by
- BiOneCure Therapeutics Inc.
- People needed
- 332
- Starts
- 2022-03-25
- Expected to finish
- 2027-04-01
- Last updated by the study team
- 2022-07-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- NEXT Oncology Austin — Austin, Texas, United States (enrolling)
- University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- NEXT Oncology Virginia — Fairfax, Virginia, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.